Trending
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Helixgate Featured2 days agoWidespread atropine use fails to sway FDA advisors on Sydnexis data
BIOCENTURY | REGULATIONWIDESPREAD ATROPINE USE FAILS TO SWAY FDA ADVISORS ON SYDNEXIS DATAPanel favors another trial to establish meaningful benefit in pediatric myopia despite clinicians’ support...
-
Helixgate Featured2 days agoAt least 11 PDUFAs on FDA’s November docket
BIOCENTURY | DATA BYTEAT LEAST 11 PDUFAS ON FDA’S NOVEMBER DOCKETPD-1 x VEGF bispecific ivonescimab first on deck
-
Helixgate Featured2 days agoFDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
PLYMOUTH MEETING, Pa., Oct. 30, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect...
-
Clinical Trials & Development2 days agoAuchincloss bill seeks to improve ‘operating system for science’
BIOCENTURY | POLITICS, POLICY & LAWAUCHINCLOSS BILL SEEKS TO IMPROVE ‘OPERATING SYSTEM FOR SCIENCE’Bill creates infrastructure to embed trials in routine care, establish Australia-style notification scheme...
-
Capital, M&A & Industry Strategy2 days agoOpentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
According to the company, the funds will support the next phase of its growth in enabling autonomous science in labs and biopharmaceutical companies using its AI...
-
AI, Machine Learning & Computational Biology2 days ago100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Parse Biosciences and Nomic Bio are partnering to create Cascade, a 100-million-cell multimodal dataset combining single-cell and proteomic data to advance AI-driven immune modeling, drug discovery,...
-
Synthetic Biology, Genomics & Advanced Therapeutics2 days agoWhat made Estuary’s kidney gene therapy bet investable
BIOCENTURY | FINANCEWHAT MADE ESTUARY’S KIDNEY GENE THERAPY BET INVESTABLEA $93M series A backs the prospect of a one-time treatment as pharmas advance competing modalities in...
-
Capital, M&A & Industry Strategy2 days agoThe impact of Gilde’s Impact Council with Joep Muijrers
BIOCENTURY | FINANCETHE IMPACT OF GILDE’S IMPACT COUNCIL WITH JOEP MUIJRERS How Gilde’s outside expert panel and deeper patient engagement have shaped the firm’s investment strategy
-
Regulatory Intelligence & Drug Approvals2 days agoPostmarketing Requirements and Commitments: Searchable Database
Learn more about FDA's Postmarketing Requirements and Commitments Searchable Database.
-
Regulatory Intelligence & Drug Approvals2 days agoFDA Rationale for Breakpoints Recognition Decision: Minocycline for Stenotrophomonas maltophilia
FDA Rationale for Breakpoints Recognition Decision: Minocycline for Stenotrophomonas maltophilia
